医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sinocare Group Closes Acquisition of Nipro Diagnostics

2016年01月08日 AM02:26
このエントリーをはてなブックマークに追加


 

FT. LAUDERDALE, Fla.

Nipro Diagnostics announced today that its acquisition by Sinocare Group has been completed. The company also announced that with completion of the acquisition, the company has been renamed Trividia Health. Scott Verner, who was Chairman, CEO and President of Nipro Diagnostics, has been named CEO and President of Trividia Health and will be joined by key executives from his current management team. The company will remain in the United States.

“Like Sinocare, Nipro Diagnostics has the long-term vision of being a leading global health and wellness company that offers innovative, high-value solutions so patients can live healthier lives,” Sinocare Chairman and CEO Shaobo Li said. “We have a great deal of respect for what the management team and employees have accomplished at Nipro Diagnostics, and we are confident in their ability to accelerate our shared vision. Joined together, our proven portfolio of products and services, our combined future direction and our strong confidence in the people who design, manufacture and sell our products and services, will be vital to attaining our shared goals.”

“Our company has experienced strong growth as a result of our new product launch cadence and our investments in highly sophisticated manufacturing and distribution facilities in the United States. This is an exciting next chapter for our combined company. I’m proud to have led the company through many changes in the public and private markets. I look forward to maximizing the global potential of our portfolio of solutions for patients, healthcare providers and our customers,” said Trividia Health CEO Scott Verner.

The new name, Trividia Health, signals the company’s new trajectory and represents the values, vision and market of the global enterprise. “TRI” honors Sinocare’s three commitments to customers, employees and shareholders; “VI” stands for the commitment to patient victory over diabetes and other health challenges; and “DIA” refers to the company’s core diabetes foundation. Finally, HEALTH was added to the name to signal the company’s new focus on developing integrated health solutions beyond diabetes.

About Trividia Health

Trividia Health, Inc., a wholly owned subsidiary of Sinocare Group, is a global health and wellness company based in Fort Lauderdale, Florida and a leading developer, manufacturer and marketer of advanced performance products for people with diabetes. With products sold under TRUE and store brand labels, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.

About Sinocare Group

Sinocare Group consists of Sinocare, Inc., Sinocare Jianheng Diabetes Hospital, and its affiliates. Sinocare Inc., headquartered in Changsha, China, is fully dedicated to the innovation of biosensor technology, promoting diabetic self-management by using blood glucose monitoring systems, providing total diabetes services and solutions in China. Founded in 2002 and listed on the Shenzhen Stock Exchange (SHE:300298) in 2012, the company has been providing high quality and low cost blood glucose monitoring systems to the Chinese market and has been listed by Forbes as one of Asia’s 200 Best Under a Billion companies.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160107006049/en/

CONTACT

Trividia Health
Neal Bhattacharya, 1-800-342-7226 ext. 3150
nbhattacharya@niprodiagnostics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
  • GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics